Canaccord Genuity analysts revised their price target for Rocket Pharmaceuticals (NASDAQ:RCKT) down to $40 from $49, while maintaining a Buy rating on the stock. The analysts expressed increased confidence in the success of the Phase 3 trial for DESCARTES-08, leading to a 50% assumed success rate. The price target adjustment also accounts for the additional shares from the $130 million PIPE financing.

The analysts anticipate further trial design refinements in Phase 3, such as excluding seronegative and LRP4+ patients from the primary efficacy analysis, which is expected to enhance the trial's likelihood of success.